Damien Prouzeau1, Ismaël Conejero2, Peter L Voyvodic3, Carine Becamel4, Mocrane Abbar2, Jorge Lopez-Castroman2,5. 1. Adult Psychiatry Department of Nîmes University Hospital, 585 chemin du Mas de Lauze, 30900, Nîmes, France. damien.prouz@gmail.com. 2. Adult Psychiatry Department of Nîmes University Hospital, 585 chemin du Mas de Lauze, 30900, Nîmes, France. 3. Centre de Biochimie Structurale (CBS), UMR 5048, University of Montpellier, INSERM U1054, CNRS, Montpellier, France. 4. Institut de Génomique Fonctionnelle, UMR 5203, University of Montpellier, INSERM U1191, CNRS, Montpellier, France. 5. CIBERSAM, ISCIII, Madrid, Spain.
Abstract
PURPOSE OF THE REVIEW: We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. RECENT FINDINGS: Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date have had small sample sizes. One clinical trial has been conducted against a reference treatment (escitalopram) without showing a significant superiority of psilocybin in the main outcome. The neurobiological mechanisms, mostly unknown, differ from those of SSRI antidepressants. Psilocybin represents a promising alternative in the treatment of depression. Further research with larger sample sizes, particularly against reference treatments, is needed to better understand the neurobiological factors of its effects and to investigate its potential for use in everyday practice.
PURPOSE OF THE REVIEW: We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. RECENT FINDINGS: Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date have had small sample sizes. One clinical trial has been conducted against a reference treatment (escitalopram) without showing a significant superiority of psilocybin in the main outcome. The neurobiological mechanisms, mostly unknown, differ from those of SSRI antidepressants. Psilocybin represents a promising alternative in the treatment of depression. Further research with larger sample sizes, particularly against reference treatments, is needed to better understand the neurobiological factors of its effects and to investigate its potential for use in everyday practice.
Authors: Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt Journal: N Engl J Med Date: 2021-04-15 Impact factor: 91.245
Authors: Janet B W Williams; Kenneth A Kobak; Per Bech; Nina Engelhardt; Ken Evans; Joshua Lipsitz; Jason Olin; Jay Pearson; Amir Kalali Journal: Int Clin Psychopharmacol Date: 2008-05 Impact factor: 1.659
Authors: Randall T Brown; Christopher R Nicholas; Nicholas V Cozzi; Michele C Gassman; Karen M Cooper; Daniel Muller; Chantelle D Thomas; Scott J Hetzel; Kelsey M Henriquez; Alexandra S Ribaudo; Paul R Hutson Journal: Clin Pharmacokinet Date: 2017-12 Impact factor: 6.447
Authors: R L Carhart-Harris; M Bolstridge; C M J Day; J Rucker; R Watts; D E Erritzoe; M Kaelen; B Giribaldi; M Bloomfield; S Pilling; J A Rickard; B Forbes; A Feilding; D Taylor; H V Curran; D J Nutt Journal: Psychopharmacology (Berl) Date: 2017-11-08 Impact factor: 4.530
Authors: Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt Journal: Lancet Psychiatry Date: 2016-05-17 Impact factor: 27.083